Huayu Pharmaceutical (6621) announced on the 27th that it has signed a patent transfer contract with Chang Gung University to obtain the key technology patents of radiofrequency ablation (RFA) “Surgical Guidance System Patent” and “Surgical Navigation Method and System for Integrated Augmented Reality”, so as to develop more accurate and effective minimally invasive surgical medical materials in the future.
In 2005, he returned to Taiwan to work at Chang Gung University to develop the application of ultrasound in non-invasive surgery, targeted drug delivery and gene therapy. Successfully pioneered the surgical navigation system and applied it to RFA needles.
At present, Huayu Pharmaceutical Commission designs, develops and manufactures RFA-related products for the treatment of liver cancer, and has officially submitted a 510(k) premarket notification application to the US FDA on December 4 last year, and at the same time applied for a Class II medical material license in Taiwan, which is expected to be launched after obtaining the certification in the second half of this year, and will fully expand NAVIRFA’s high-quality products from Taiwan to the global minimally invasive ablation market for the treatment of liver cancer.
The global market size for RFA devices is expected to reach $3 billion by 2020 (Grand View Market Research, 2019). The NAVIRFA Scope product that assists physicians in making RFA needles is an upgraded version of the current RFA needles (RFA2.0). Before the minimally invasive surgery is performed, Huayu’s patented platform technology “Optical Tracking/Navigation System” can be used to pre-confirm the correct angle of the needle entering the skin and the path to the expected tumor area, effectively shortening the operation time and reducing the number of repeated needle insertion, and improving the medical quality of surgery.
Original news: https://ctee.com.tw/livenews/aj/ctee/A88131002021052720074387
